Back to results
US 2024/0002802 A1Published application
Modified nk-92 cells for treating cancer
AssigneeImmunityBio, Inc.
InventorTien Lee
Life of this patent
Estimating the term…
Abstract
Provided herein are NK-92 cells expressing at least one CAR and at least one Fc receptor. Also provided are methods of treatment of a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer, comprising administering to the patient NK-92-Fc-CAR.
Claims20
A method of treating a cancer in a patient in need thereof, the method comprising:
- administering to the patient an effective amount of an NK-92 cell line comprising modified NK-92 cells;
- wherein the modified NK-92 cells are each modified to express and display on the cell surface of the modified NK-92 cells at least one Fc receptor and at least one chimeric antigen receptor (CAR), wherein the CAR is capable of binding CD33 or CSPG-4 expressed on a surface of a cancer cell;
- wherein the CAR has a scFv segment that is coupled via a hinge portion to a transmembrane domain and an intracellular signaling domain;
- and
- wherein the scFv segment has the amino acid sequence of amino acids 21-266 of SEQ ID NO:11 or amino acids 21-281 SEQ ID NO:13.
2 more elements
A modified NK92-cell, wherein
- (1) the modified NK-92 cells are modified to each express at least one Fc receptor and at least one chimeric antigen receptor (CAR), such that the at least one Fc receptor and the at least one CAR are displayed on the cell surface of the modified NK-92 cells;
- (2) the CAR has a scFv segment that is coupled via a hinge portion to a transmembrane domain and an intracellular signaling domain, and wherein the CAR is capable of binding CD33 or CSPG-4 expressed on a surface of a cancer cell;
- and
- (3) the scFv segment has the amino acid sequence of amino acids 21-266 of SEQ ID NO:11 or amino acids 21-281 SEQ ID NO:13.
1 more element
Dependencies are inferred from the claim text.